Arterial Disease Multifactorial Intervention Trial (ADMIT)

July 11, 2016 updated by: National Heart, Lung, and Blood Institute (NHLBI)
To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND:

Multiple mechanisms are involved in the deposition of LDL-C into the arterial wall, and the prevention of such deposition as well as the removal of the LDL-particles. Further, there remain questions regarding what causes an existing plaque that has been stable for a long period of time to become occlusive or ulcerating and what may prevent it from doing so. Prevention and treatment are almost certain to become multifaceted and more complex when using several complementary interventions or preventive measures concomitantly.

Multifactorial prevention and treatment may be particularly useful in people with peripheral arterial disease. PAD as manifested by intermittent claudication affects about 0.5 to 1.0 percent of individuals above age 35, with a twofold predominance in men. There is a strikingly increased incidence with age in both sexes, particularly in those above age 50. Mortality in patients with intermittent claudication has been shown to be six times higher than in other people of similar age and gender. The excess in mortality is primarily due to a ninefold increase in cardiovascular disease (CVD) deaths. Those who have asymptomatic but measurable PAD (two to two-and-a-half times as many as have intermittent claudication), have relative risks of about 3 and 4 for total and CVD mortality, respectively. Therefore, interventions that prevent the development or progression of atherosclerotic disease or reduce arterial thrombosis should reduce mortality and morbidity due to myocardial infarction and stroke while favorably affecting the morbidity directly associated with PAD.

The National Cholesterol Education Program (NCEP) has included peripheral vascular disease (PVD) in its guidelines as a risk factor in the Classification and Decision for Treatment Algorithm. This means that patients who have PVD and elevated LDL-C and one other risk factor such as male gender, family history, cigarette smoking, or hypertension, should have appropriate dietary intervention followed by drug therapy as needed. Even with the guidelines in place since the end of 1987, a survey of PVD patients referred to a major medical center clinic found that very few patients were on lipid lowering therapy, either diet or drug. The reason for the primary care community not modifying lipids in these high risk patients may be related to lack of studies demonstrating benefit of lipid modification in those who have PVD. It is anticipated that many patients with PAD will require treatment for elevated LDL-C. It is not as clear whether interventions aimed at raising HDL-C will result in a slowing of progression of atherosclerosis in this population.

Platelets have been shown to have a key role in the development of occlusive atherosclerosis and thrombosis related to coronary heart disease. Inhibition of platelet function has been postulated to slow progression of atherosclerosis; specifically, aspirin has been demonstrated to reduce lipoprotein deposition in the arterial wall of nonhuman primates. This deposition is even further reduced by the addition of a lipid lowering regimen to the antiplatelet regimen. It remains unclear whether mini-dose, less intense anticoagulation is the most appropriate antithrombotic therapy in people with PAD who are also receiving lipid modifying agents.

DESIGN NARRATIVE:

Patients were randomized to a control arm or to one of three treatment arms, including a lipid modification arm, an antioxidant arm, and an antithrombotic arm. Patients in the lipid modification arm were randomized to placebo or treated with nicotinic acid to increase HDL while lowering LDL levels equally with the hydroxymethylglutaryl-coenzyme A reductase inhibitor pravastatin as needed in the intervention and control groups. Patients in the antioxidant arm were assigned to daily doses of 24 mg. of beta-carotene, 800 IU of vitamin E, and 1.0 g of vitamin C or to placebo. Patients in the antithrombotic arm received 2 mg/day of active or placebo warfarin taken daily until the fifth follow-up visit. Patients were followed every six weeks after entry for one year of follow-up. The primary endpoint of the study was the efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations. The secondary endpoints were to determine the efficacy of the HDL-C raising arm to achieve an increase in HDL-C in the treatment group while also obtaining equivalent reductions in LDL-C in the treatment and control groups, to assess the dose-response of niacin on HDL-C raising, to determine if the combination of low-dose warfarin plus aspirin versus aspirin alone had the expected impact on the hemostatic system, to determine if combination antioxidant therapy (vitamins E and C and beta carotene) led to changes in biomarkers for antioxidants, and to determine the interaction of the lipid altering strategy with antioxidants for effects on biomarkers for antioxidants. Screening began August 1, 1993, randomization began December 1, 1993 and ended December 31, 1994 with a total of 468 patients enrolled. Support for the trial ended in September 1995. Data analysis continues through March 31, 1999 under contract N01HC35124.

The study completion date listed in this record was obtained from the "Completed Date" entered in the Query View Report System (QVR).

Study Type

Interventional

Phase

  • Phase 3

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Men and women with symptomatic or asymptomatic peripheral arterial disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Investigators

  • Kathryn Davis, Statistics and Epidemiology Research Corporation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 1992

Primary Completion

December 7, 2022

Study Completion (Actual)

March 1, 1999

Study Registration Dates

First Submitted

October 27, 1999

First Submitted That Met QC Criteria

October 27, 1999

First Posted (Estimate)

October 28, 1999

Study Record Updates

Last Update Posted (Estimate)

July 12, 2016

Last Update Submitted That Met QC Criteria

July 11, 2016

Last Verified

January 1, 2006

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 82

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Diseases

Clinical Trials on niacin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe